DE10160409A1 - Fat resorption composition, useful for treating obesity in humans and animals, comprises ionic and/or nonionic cellulose ether that forms a gel in the gastro-intestinal tract - Google Patents
Fat resorption composition, useful for treating obesity in humans and animals, comprises ionic and/or nonionic cellulose ether that forms a gel in the gastro-intestinal tractInfo
- Publication number
- DE10160409A1 DE10160409A1 DE10160409A DE10160409A DE10160409A1 DE 10160409 A1 DE10160409 A1 DE 10160409A1 DE 10160409 A DE10160409 A DE 10160409A DE 10160409 A DE10160409 A DE 10160409A DE 10160409 A1 DE10160409 A1 DE 10160409A1
- Authority
- DE
- Germany
- Prior art keywords
- gel
- gastro
- humans
- animals
- nonionic cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 8
- 229920003086 cellulose ether Polymers 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- 241001465754 Metazoa Species 0.000 title description 3
- 208000008589 Obesity Diseases 0.000 title description 3
- 235000020824 obesity Nutrition 0.000 title description 3
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000003925 fat Substances 0.000 claims description 7
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 239000003349 gelling agent Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 229950008138 carmellose Drugs 0.000 claims description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001761 ethyl methyl cellulose Substances 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 235000013367 dietary fats Nutrition 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
- 229960001243 orlistat Drugs 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001975 sympathomimetic effect Effects 0.000 description 2
- 229940064707 sympathomimetics Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Gegenstand der Erfindung ist ein Mittel, das nach oraler Einnahme beim Menschen oder bei Tieren im Magen-Darm-Trakt das Ausmaß der Resorption von Nahrungsfetten reduziert. Aufgrund der verminderten Resorption von Nahrungsfetten ist ein Einsatz des erfindungsgemäßen Mittels bei Reduktionsdiäten zur Reduzierung der aufgenommenen Kalorienmenge sowie zur Senkung des Cholesterolspiegels vorgesehen. The invention relates to an agent that after oral ingestion Humans or animals in the gastrointestinal tract the extent of absorption reduced by dietary fats. Due to the reduced absorption of Dietary fats are used in the agent according to the invention Reduction diets to reduce the amount of calories consumed as well intended to lower cholesterol.
Übergewicht wird beim Menschen oder Tieren (z. B. Hunden) durch die übermäßige Aufnahme kalorienreicher Nahrung verursacht. Obesity is caused by humans or animals (e.g. dogs) causes excessive intake of high-calorie food.
Bisher werden zur Behandlung von Übergewicht neben diätetischen Maßnahmen vorwiegend pflanzliche oder chemisch definierte Abmagerungsmittel oder Appetitzügler verwendet. Pflanzliche Abmagerungsmittel enthalten Quellmittel wie Alginsäure oder Karaya-Gummi, die aufgrund ihres Volumenreizes sättigend wirken sollen. So far, have been used to treat obesity in addition to dietary Measures mainly vegetable or chemically defined Weight loss agents or appetite suppressants used. vegetable Slimming agents contain swelling agents such as alginic acid or karaya gum, which should have a satiating effect due to their volume stimulus.
Im Weiteren werden Sypathomimetika als Appetitzügler zur Unterstützung der Gewichtsreduktion verwendet. Sympathomimetika sollen anregend wirken und der bei Reduktionsdiäten auftretende Müdigkeit entgegenwirken. In addition, hypomometics are used to suppress appetite Weight loss used. Sympathomimetics should have a stimulating effect counteract the tiredness that occurs with reduction diets.
Sympathomimetika werden in den Blutkreislauf aufgenommen. Sie können erhebliche Nebenwirkungen wie Bluthochdruck auslösen. Sympathomimetics are absorbed into the bloodstream. You can trigger significant side effects such as high blood pressure.
Bei Reduktionsdiäten kann versucht werden, die Resorption von Nahrungsfetten durch Lipase-Hemmstoffe wie z. B. Orlistat zu vermindern (U.S. Patent 4,598,089). Orlistat wird in Kapseln abgefüllt und zur Gewichtsreduktion im Rahmen von Reduktionsdiäten eingesetzt. Orlistat soll im Magen-Darm-Trakt die für die Resorption bestimmter Nahrungsfette erforderliche Fettspaltung verhindern. Orlistat greift damit in metabolische Vorgänge im Körper ein. Es werden zahlreiche Nebenwirkungen beschrieben, die weitere pharmakologische Aktivitäten der Substanz im Körper vermuten lassen. In the case of reduction diets, the absorption of Dietary fats through lipase inhibitors such as B. Reduce Orlistat (U.S. Patent 4,598,089). Orlistat is filled into capsules and used for Weight loss used in the context of reduction diets. Orlistat is said to in the gastrointestinal tract are those for the absorption of certain dietary fats Prevent necessary fat splitting. Orlistat thus intervenes in metabolic Processes in the body. Numerous side effects are described who suspect further pharmacological activities of the substance in the body to let.
Die Nachteile, die in den Nebenwirkungen der bisher bekannten Mittel zur Gewichtsreduktion bzw. zur Reduzierung der Fettresorption liegen, werden durch die vorliegende Erfindung behoben. Durch die Gabe von ionischen oder nichtionischen Celluloseethern oder ihren Mischungen als Gelbildner wird im Magen-Darm-Trakt die Resorption der Nahrungsfette ganz oder teilweise verhindert. Die Gelbildner verhindern ganz oder teilweise die Mizellbildung der Nahrungsfette mit den Gallensäften, die vollständige Fettspaltung und damit die Resorption Fette bzw. Fettsäuren. The disadvantages in the side effects of the previously known means of Weight reduction or to reduce fat absorption are resolved by the present invention. By giving ionic or nonionic cellulose ethers or their mixtures as gelling agents is used in Gastrointestinal tract all or part of the absorption of dietary fats prevented. All or part of the gelling agents prevent micelle formation Dietary fats with the bile juices, the complete fat splitting and thus the absorption of fats or fatty acids.
Die ionischen oder nichtionischen Celluloseether werden als Lösungen, Suspensionen, Pulver und Granulate oder in Form von Tabletten und Kapseln gegeben. The ionic or nonionic cellulose ethers are used as solutions, Suspensions, powders and granules or in the form of tablets and capsules given.
Als Celluloseether wird vorzugsweise Hydroxyethylcellulose mit einer hohen Viskosität gegeben. Hydroxyethylcellulose wird als Lösung oder wässrige Suspension vor, zu oder nach den Mahlzeiten eingenommen. Eine bevorzugte Zubereitungsform ist eine wässrige Suspension, die erst nach der Einnahme im Magen eine gelartige Konsistenz ausbildet. The preferred cellulose ether is hydroxyethyl cellulose with a high Given viscosity. Hydroxyethyl cellulose is used as a solution or aqueous Suspension taken before, with or after meals. A preferred one Formulation is an aqueous suspension that is only after ingestion develops a gel-like consistency in the stomach.
Die für das erfindungsgemäße Mittel verwendeten Cellulosedderivate werden praktisch nicht resorbiert. Sie besitzen keine Nebenwirkungen. The cellulose derivatives used for the agent according to the invention are practically not absorbed. They have no side effects.
Beispiele für ionische oder nichtionische Gelbildner zur Herstellung des
erfindungsgemäßen Mittels sind Carmellose, Hypromellose,
Hydroxyethylcellulose, Hydroxypropylcellulose, Ethylmethylcellulose und
Methylcellulose. Weitere Gelbildner anderer Stoffklassen wie z. B.
Stärkederivate können zur Unterstützung der Gelbildung eingesetzt werden.
Herstellungsbeispiel 1
Hydroxyethylcellulose 30.000 3 g
Modifizierte Stärke 1 g
Examples of ionic or nonionic gel formers for the preparation of the agent according to the invention are carmellose, hypromellose, hydroxyethyl cellulose, hydroxypropyl cellulose, ethyl methyl cellulose and methyl cellulose. Other gelling agents of other substance classes such as B. Starch derivatives can be used to support gel formation. Production Example 1 Hydroxyethylcellulose 30,000 3 g
Modified starch 1 g
Die Bestandteile werden gemischt und zu einem Granulat verarbeitet. The ingredients are mixed and processed into granules.
8 Patienten erhielten an 3 Tagen mit den Mahlzeiten (3 × täglich) jeweils 30 g Pflanzenfett. Direkt nach den Mahlzeiten wurden 4 g des im Herstellungsbeispiel 1 beschriebenen Mittels in Wasser eingerührt gegeben. An den folgenden Tagen wurden durchschnittlich täglich etwa 30 g der Nahrungsfette als Fettsäure oder Neutralfette in den Faeces ausgeschieden. Ohne das Mittel gelangen lediglich etwa 8 g Nahrungsfette in den Stuhl. Eight patients received 30 g vegetable fat on three days with meals (3 times a day). Immediately after meals, 4 g of the agent described in Preparation 1 were added to water. On the following days, an average of about 30 g of dietary fats were excreted in the faeces as fatty acid or neutral fats. Without the remedy, only about 8 g of dietary fats get into the stool.
Claims (3)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10160409A DE10160409A1 (en) | 2001-12-10 | 2001-12-10 | Fat resorption composition, useful for treating obesity in humans and animals, comprises ionic and/or nonionic cellulose ether that forms a gel in the gastro-intestinal tract |
| PCT/EP2002/013032 WO2003053451A1 (en) | 2001-12-10 | 2002-11-21 | Use of ionic and non-ionic cellulose ethers for producing a gel-like agent for preventing the resorption of fats from the gastro-intestinal tract |
| AU2002352075A AU2002352075A1 (en) | 2001-12-10 | 2002-11-21 | Use of ionic and non-ionic cellulose ethers for producing a gel-like agent for preventing the resorption of fats from the gastro-intestinal tract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10160409A DE10160409A1 (en) | 2001-12-10 | 2001-12-10 | Fat resorption composition, useful for treating obesity in humans and animals, comprises ionic and/or nonionic cellulose ether that forms a gel in the gastro-intestinal tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10160409A1 true DE10160409A1 (en) | 2003-06-18 |
Family
ID=7708551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10160409A Withdrawn DE10160409A1 (en) | 2001-12-10 | 2001-12-10 | Fat resorption composition, useful for treating obesity in humans and animals, comprises ionic and/or nonionic cellulose ether that forms a gel in the gastro-intestinal tract |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2002352075A1 (en) |
| DE (1) | DE10160409A1 (en) |
| WO (1) | WO2003053451A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008051794A2 (en) | 2006-10-20 | 2008-05-02 | Dow Global Technologies Inc. | Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
| WO2008051793A3 (en) * | 2006-10-20 | 2008-06-19 | Dow Global Technologies Inc | Method of preventing or treating metabolic syndrome |
| WO2010045532A1 (en) * | 2008-10-17 | 2010-04-22 | Dow Global Technologies Inc. | Methods of reducing absorption of trans fatty acids using water-insoluble cellulose derivatives |
| CN102291998A (en) * | 2008-10-17 | 2011-12-21 | 陶氏环球技术有限责任公司 | Method of reducing absorption of trans fatty acids using water-soluble cellulose derivatives |
| WO2013059065A1 (en) * | 2011-10-19 | 2013-04-25 | Dow Global Technologies Llc | Methods and compositions for inducing satiety |
| WO2013059064A1 (en) * | 2011-10-19 | 2013-04-25 | Dow Global Technologies Llc | Methods and compositions for inducing satiety |
| US8623840B2 (en) | 2010-04-29 | 2014-01-07 | Dow Global Tchnologies LLC | Methods and compositions for inducing satiety |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Method of treating men with metabolic and anthropometric disorders |
| EP2170930B3 (en) | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP2011522828A (en) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| JP6606491B2 (en) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | Ultra high purity agonist of guanylate cyclase C, method for producing and using the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE466130B (en) * | 1990-11-22 | 1992-01-07 | Kabi Pharmacia Ab | GEL PHOTOGRAPHY LIQUID DIET FIBER COMPOSITION |
| CA2342625A1 (en) * | 1998-09-08 | 2000-03-16 | Smithkline Beecham Corporation | Lipstatin derivative-soluble fiber tablets |
-
2001
- 2001-12-10 DE DE10160409A patent/DE10160409A1/en not_active Withdrawn
-
2002
- 2002-11-21 AU AU2002352075A patent/AU2002352075A1/en not_active Abandoned
- 2002-11-21 WO PCT/EP2002/013032 patent/WO2003053451A1/en not_active Application Discontinuation
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008051794A2 (en) | 2006-10-20 | 2008-05-02 | Dow Global Technologies Inc. | Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
| WO2008051794A3 (en) * | 2006-10-20 | 2008-06-19 | Dow Global Technologies Inc | Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
| WO2008051793A3 (en) * | 2006-10-20 | 2008-06-19 | Dow Global Technologies Inc | Method of preventing or treating metabolic syndrome |
| WO2010045535A3 (en) * | 2008-10-17 | 2013-06-13 | Dow Global Technologies Llc. | Method of reducing absorption of trans fatty acids using water-soluble cellulose derivatives |
| CN102202521B (en) * | 2008-10-17 | 2013-09-18 | 陶氏环球技术有限责任公司 | Methods of reducing absorption of trans fatty acids using water-insoluble cellulose derivatives |
| JP2012505661A (en) * | 2008-10-17 | 2012-03-08 | ダウ グローバル テクノロジーズ エルエルシー | Method for reducing absorption of trans fatty acid using water-insoluble cellulose derivative |
| CN102291998A (en) * | 2008-10-17 | 2011-12-21 | 陶氏环球技术有限责任公司 | Method of reducing absorption of trans fatty acids using water-soluble cellulose derivatives |
| WO2010045532A1 (en) * | 2008-10-17 | 2010-04-22 | Dow Global Technologies Inc. | Methods of reducing absorption of trans fatty acids using water-insoluble cellulose derivatives |
| US8623840B2 (en) | 2010-04-29 | 2014-01-07 | Dow Global Tchnologies LLC | Methods and compositions for inducing satiety |
| WO2013059064A1 (en) * | 2011-10-19 | 2013-04-25 | Dow Global Technologies Llc | Methods and compositions for inducing satiety |
| WO2013059065A1 (en) * | 2011-10-19 | 2013-04-25 | Dow Global Technologies Llc | Methods and compositions for inducing satiety |
| CN103889246A (en) * | 2011-10-19 | 2014-06-25 | 陶氏环球技术有限责任公司 | Methods and compositions for inducing satiety |
| CN103917109A (en) * | 2011-10-19 | 2014-07-09 | 陶氏环球技术有限责任公司 | Methods and compositions for inducing satiety |
| US9216191B2 (en) | 2011-10-19 | 2015-12-22 | Dow Global Technologies Llc | Methods and composition for inducing satiety |
| CN103889246B (en) * | 2011-10-19 | 2015-12-23 | 陶氏环球技术有限责任公司 | Induction produces the method and composition of satiety |
| US9295712B2 (en) | 2011-10-19 | 2016-03-29 | Dow Global Technologies Llc | Methods and composition for inducing satiety |
| CN103917109B (en) * | 2011-10-19 | 2018-02-06 | 陶氏环球技术有限责任公司 | The method and composition of inducing satiety |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003053451A1 (en) | 2003-07-03 |
| AU2002352075A1 (en) | 2003-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE10160409A1 (en) | Fat resorption composition, useful for treating obesity in humans and animals, comprises ionic and/or nonionic cellulose ether that forms a gel in the gastro-intestinal tract | |
| DE69107046T2 (en) | Food and drink containing algin. | |
| EP0575846B1 (en) | Food and feedstuff containing lipase inhibitors | |
| DE2919449C2 (en) | Dietary agent for natural digestive regulation | |
| DE102008036954B4 (en) | Use of an amino sugar-containing composition | |
| US5932561A (en) | Dietary composition with lipid binding properties for weight management and serum lipid reduction | |
| EP1494655A1 (en) | Agent for producing a sensation of satiety and for weight loss | |
| DE60132444T2 (en) | TREATING IRRITATION SYNDROME OR DISEASE | |
| DE602004006860T2 (en) | CAPSAICINOID-CONTAINING PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
| CN104814901B (en) | One kind prevention striae of pregnancy gel and preparation method thereof | |
| DE10060750A1 (en) | Food supplement product for intestinal activation | |
| DE20205184U1 (en) | Blood lipid lowerers for oral use | |
| DE19528524C2 (en) | Calcium-containing agent for intestinal phosphate binding and process for its preparation | |
| DE10214005A1 (en) | Orally administered dietetic, nutritional supplement or medicament composition, useful as hypolipemic agent, comprising mixture of pectin and/or guar powder with eicosapentaenoic and docosahexaenoic acids | |
| DE69232126T3 (en) | Ingestible preparations containing water-soluble, highly viscous cellulose ethers | |
| DE10044846A1 (en) | Agent with prolonged gastric residence time to produce a long-lasting satiety effect and its use | |
| DE3316597C1 (en) | Gelatinous preparation, and the use thereof as a medicament | |
| CN1138296A (en) | Application of simethicone in treating constipation | |
| DE202011004425U1 (en) | Composition for use in indigestion | |
| DE102017119313B4 (en) | Bile acid-containing appetite suppressant | |
| DE202008002263U1 (en) | Health promoting agent and its use | |
| CH620124A5 (en) | Magnesium chloride tablets and process for their production | |
| US20100166888A1 (en) | Composition and method for the control of organoleptic properties of bodily fluids and secretions | |
| WO2002069987A2 (en) | Agent for treating diabetes mellitus | |
| DE102008009752A1 (en) | Beverage for improving the state of health, contains chili pepper juice and grape fruit juice that are mixed to the beverage without alcohol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |